,k on behalf of the DAPT Study Investigators ABSTRACT BACKGROUND The DAPT (Dual Antiplatelet Therapy) study enrolled patients after coronary stenting. Patients
was associated with a reduction in major adverse cardiovascular events (5) . In both studies, continuation of platelet P2Y 12 inhibition was associated with increased bleeding risk.
The DAPT score is a novel decision tool that was recently developed to determine, among patients eligible for long-term dual antiplatelet therapy, those more likely to derive benefit (vs. harm) from long-term therapy (6) . The ability of the DAPT score to effectively stratify relative ischemic benefit versus bleeding risk associated with prolonged thienopyridine therapy among patients with established ischemic risk (ACS or prior MI) and those without a history of MI is unknown.
Thus, we analyzed ischemic and bleeding events among patients enrolled into the DAPT study by MI status (prior MI, index MI, any MI, or no MI) and DAPT score among eligible patients randomized to continued thienopyridine (vs. placebo) therapy in combination with aspirin between 12 and 30 months following PCI.
METHODS
The DAPT study was a double-blind, international, multicenter, randomized, placebo-controlled trial designed to compare 30 with 12 months of aspirin plus thienopyridine therapy (clopidogrel or prasugrel) after coronary stenting with either drug-eluting stents or bare-metal stents. The study design (7) and results (2) (3) (4) 8) have been described previously, as has the DAPT score (6) .
The present exploratory analysis of patients who tolerated dual antiplatelet therapy for 1 year was designed to evaluate the risk of ischemic and bleeding events according to the time interval between presentation with MI and PCI; and determine the ability of the DAPT score to predict relative benefit (vs. harm) from continued thienopyridine therapy among individual patients beyond the benefitrisk strata conferred by MI status (any or none) alone.
STUDY POPULATION AND PROCEDURES. After PCI with either drug-eluting stents or bare-metal stents, patients who were candidates for dual antiplatelet therapy were enrolled and treated with open-label thienopyridine (clopidogrel or prasugrel) in combination with aspirin for 12 months. At 12 months, patients without a major adverse cardiovascular or cerebrovascular event, repeat revascularization, or moderate or severe bleeding but who were compliant with dual antiplatelet therapy were randomized to receive thienopyridine plus aspirin or placebo plus aspirin for an additional 18 months. At 30 months, the randomized study drug was discontinued; all patients remained on aspirin alone and were followed for another 3 months.
The institutional review board at each participating institution approved the study and all patients provided written, informed consent.
For the purposes of this study, patients were categorized according to the timing of MI, with "index MI" occurring within 72 h before the index PCI, "prior MI" defined as occurring more than 72 h before the index PCI, "no MI" described patients with neither index nor prior MI, and "any MI" used to describe patients with either index or prior MI. DAPT SCORE. The derivation and validation of the DAPT score has previously been described for all randomized patients in the DAPT study (6) . The DAPT score, ranging from -2 to 10, included several variables pertinent to event risk (Central Illustration).
Overall, lower DAPT scores were associated with higher bleeding risk (with or without continued thienopyridine therapy) and less ischemic benefit from treatment, whereas higher DAPT scores were associated with lower bleeding risk and larger absolute ischemic benefit. Table 5 , Central Illustration, Figures 3 and 4) . Results were consistent among randomized patients not treated with paclitaxel-eluting stents (Online Figure 1) . Kereiakes et al. In prior analysis, the DAPT score was able to identify patients in the overall DAPT study with greater ischemic benefit (DAPT score $2) or greater bleeding risk (DAPT score <2). Higher DAPT scores indicated greater MI/ST reduction (p interaction < 0.001) and lower DAPT scores indicated greater bleeding risk increases (p interaction ¼ 0.02) with continued thienopyridine therapy (6) . Of note, the DAPT score includes a history of MI and, therefore, by definition patients with any MI would be expected to have higher scores. Nonetheless, in the current study, the score still differentiated between those who would benefit from or be harmed by continued thienopyridine use among patients within each of these groups. In this regard, it is noteworthy that 35% of the no MI cohort had high DAPT scores that would predict ischemic benefit exceeding bleeding risk, whereas 30% of the any MI cohort had low DAPT scores that DAPT Score
DISCUSSION
No MI
clinical utility of the DAPT score to improve decision making over the single subgroup classification by MI status was evident in terms of number needed to treat to benefit or harm ( Table 4 ). The number needed to treat to benefit to avoid MI/ST in the no MI population was reduced from 84 to 40 when patients with a high DAPT score were selected. For patients with any MI, the number needed to treat to harm resulting in bleeding was increased from 106 to 226 when patients with a high DAPT score were selected.
Because some patients with MI have high risk of bleeding and some patients without MI have high risk of ischemia, using the determinant of MI history alone to decide treatment duration is inadequate.
Importantly, the DAPT score allowed for more refined decision making and identified which patients with a history of MI have a risk of bleeding that outweighed any ischemic benefit from longer duration therapy.
Conversely, among patients with no history of MI, a high DAPT score predicted ischemic risk DAPT ¼ dual antiplatelet therapy; NNTB ¼ number needed to treat to benefit; NNTH ¼ number needed to treat to harm; other abbreviations as in Tables 1, 2 , and 3.
PERSPECTIVES COMPETENCY IN PATIENT CARE AND PROCEDURAL

SKILLS:
The DAPT score may be useful in assessing the risks and benefits of continuing dual antiplatelet therapy for more than 12 months after coronary stenting. The score incorporates patient age, cigarette smoking, diabetes, myocardial infarction at presentation or earlier, prior coronary interventions, stent type and diameter, heart failure, and left ventricular ejection fraction.
Among the additional factors to consider are medication compliance and the occurrence of major ischemic or bleeding events during the initial treatment period.
TRANSLATIONAL OUTLOOK: Prospective studies are required to validate the predictive value of the dual antiplatelet therapy score in diverse patient cohorts over shorter and longer periods of treatment exposure.
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